Relmada Therapeutics, Inc. RLMD Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s payments to acquire short-term investments?
- Relmada Therapeutics, Inc. (RLMD) reported payments to acquire short-term investments of $149.52M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s payments to acquire short-term investments changed year-over-year?
- Relmada Therapeutics, Inc.'s payments to acquire short-term investments increased by 30544.1% year-over-year, from $487.92K to $149.52M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s payments to acquire short-term investments?
- Over 3 years (2022 to 2025), Relmada Therapeutics, Inc.'s payments to acquire short-term investments has grown at a 21.0% compound annual growth rate (CAGR), from $47.29M to $83.83M.
- What does payments to acquire short-term investments mean?
- The total cash outflow used to purchase liquid financial instruments or marketable securities with maturities of one year or less. It indicates the company's strategy for deploying excess cash to earn interest while maintaining liquidity.